Top Page
Adherium Ltd.
(Sydney:ADR)
Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)
Adherium Ltd. Business Overview & Revenue Model
Adherium Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 964.13K | 840.98K | 3.19M | 529.00K | 401.00K | 2.22M | Gross Profit |
| -246.95K | 267.70K | 1.69M | -690.00K | -789.00K | 677.00K | EBIT |
| -12.53M | -12.09M | -11.91M | -12.84M | -12.37M | -8.92M | EBITDA |
| -12.44M | -11.56M | -9.91M | -12.65M | -12.74M | -8.46M | Net Income Common Stockholders |
| -11.33M | -10.22M | -9.86M | -10.04M | -15.04M | -11.40M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 387.21K | 6.20M | 9.08M | 5.28M | 15.18M | 4.58M | Total Assets |
| 4.87M | 9.89M | 12.68M | 8.53M | 17.04M | 6.72M | Total Debt |
| 752.96K | 93.20K | 44.00K | 85.00K | 0.00 | 0.00 | Net Debt |
| 365.75K | -6.10M | -9.03M | -5.20M | -15.18M | -4.58M | Total Liabilities |
| 3.46M | 3.41M | 3.47M | 3.00M | 3.00M | 3.33M | Stockholders Equity |
| 1.41M | 6.48M | 9.21M | 5.54M | 14.04M | 3.38M |
| Cash Flow | Free Cash Flow | ||||
| -11.18M | -10.61M | -9.32M | -9.89M | -11.30M | -7.46M | Operating Cash Flow |
| -11.17M | -10.61M | -9.28M | -9.61M | -11.27M | -7.32M | Investing Cash Flow |
| -14.70K | -37.00 | -41.00K | -279.00K | -29.00K | -138.00K | Financing Cash Flow |
| 8.40M | 7.73M | 13.07M | 0.00 | 21.90M | 11.34M |
Adherium Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
54 Neutral | AU$8.10M | 6.83 | 26.99% | ― | ― | 51.85% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
53 Neutral | AU$699.91M | ― | -112.97% | ― | ― | -84.82% | |
53 Neutral | AU$647.09M | ― | -56.99% | ― | 10.76% | -195.89% | |
51 Neutral | AU$31.68M | ― | -7.59% | ― | 28.89% | 72.95% | |
47 Neutral | AU$5.31M | ― | -375.15% | ― | -59.01% | 17.06% |
Adherium Ltd. Corporate Events
Adherium Limited announced the issuance of 2,000,000 stock appreciation rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted, reflecting the company’s strategy to incentivize and retain key personnel.
Adherium Limited announced a change in the director’s interest, with George Baran acquiring 1,200,000 convertible notes. This acquisition follows shareholder approval and reflects ongoing strategic financial maneuvers within the company, potentially impacting its market positioning and stakeholder interests.
Adherium Ltd. announced the issuance of 2,225,000 convertible notes, which are unquoted equity securities. This move is part of the company’s financial strategy to enhance its capital structure, potentially impacting its market position by providing additional resources for growth and development in the digital health sector.
Adherium Limited has announced a proposed issuance of 900,000 convertible notes, scheduled for November 10, 2025. This move is part of a strategic effort to raise capital, potentially impacting the company’s financial structure and market positioning, and offering new opportunities for stakeholders.
Adherium Limited has announced a successful capital raise of $900,000 through the issuance of convertible notes, supported by Phillip Asset Management Limited and Trudell Medical Limited. The funds will be used to further the roll-out of the Hailie® Smartinhaler® platform in the U.S. and for general working capital, potentially strengthening Adherium’s market position in digital health solutions for respiratory care.
Adherium Ltd. has announced the appointment of Keven Gessner as a director, effective May 8, 2025. As part of his role, Gessner holds 2,000,000 Stock Appreciation Rights, indicating a significant interest in the company’s future performance. This appointment is a strategic move that could influence Adherium’s market positioning and operational strategies, potentially impacting stakeholders positively by aligning leadership with shareholder interests.
Adherium Limited has announced that William Hunter has ceased to be a director of the company as of May 8, 2025. The notice details Hunter’s interests in the company’s securities, which include 174,170 fully paid ordinary shares. This change in directorship may impact the company’s governance and strategic direction, but specific implications for stakeholders or the company’s operations are not detailed in the announcement.
Adherium Limited has announced key leadership appointments to bolster its strategic marketing and sales efforts for the Hailie® Smartinhaler® platform in the US. The appointments include Keven Gessner as Non-Executive Director, Jason Hochman as Head of US Commercial/GTM, and David Haddad as Head of Product. These strategic hires aim to enhance Adherium’s market presence and accelerate its commercial growth in the US healthcare market, leveraging their extensive experience in digital health and respiratory care. The company’s recent capital raise of $2.6 million further supports its commitment to expanding its operations and driving the adoption of its technology.
Adherium Limited has reported significant growth in its US commercial patient base, with a more than 100% increase in the last quarter, reaffirming its target of 9,000 remote patient monitoring patients by the end of 2025. The company has expanded its US commercialization team and released a new Hailie Smartinhaler product compatible with AstraZeneca’s AIRSUPRA and Breztri Aerosphere, enhancing its market position and offering significant opportunities for growth. Strategic partnerships with Group Purchasing Organizations and other healthcare providers are expected to streamline adoption and drive further expansion, while the integration of AI-driven algorithms aims to improve patient adherence and care management.
Adherium Limited announced that all resolutions at their Extraordinary General Meeting were passed. These resolutions included the approval and ratification of the issuance of convertible notes to various entities, indicating a strategic move to enhance financial flexibility and potentially expand their market presence.
Adherium Limited announced the cessation of certain securities, including 394,753 ordinary fully paid shares and 3,600,447 stock appreciation rights, due to unmet conditions and the expiry of options. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth prospects.
Adherium Ltd. has announced the issuance of 75,000,000 unquoted convertible notes as part of a previously announced transaction. This move is expected to impact the company’s financial structure and could influence its market positioning by providing additional capital for operations and strategic initiatives.
Adherium Limited has announced a proposed issue of securities, including 445,000,000 convertible notes and 222,500,000 unlisted options exercisable at $0.02, with an expiration of three years from the issue date. This move is part of a placement or other type of issue, with the proposed issue date set for April 30, 2025. The issuance aims to enhance Adherium’s financial resources, potentially impacting its market positioning and offering new opportunities for stakeholders.
Adherium Ltd. announced a proposed issue of securities, including 75 million convertible notes and 37.5 million unlisted options. This move is part of a strategic effort to raise capital, potentially impacting the company’s financial position and market operations by providing resources for growth and development.
Adherium Ltd. has released a presentation highlighting its strategic focus on revolutionizing respiratory care through intelligent data. The announcement outlines potential risks and uncertainties associated with product development, regulatory approvals, and market penetration, emphasizing the challenges faced by companies in the medical device sector. Despite these challenges, Adherium remains committed to achieving its objectives and milestones, although there is no guarantee of meeting forecasts or realizing forward-looking statements.
Adherium Limited has secured $2.6 million through a convertible note capital raise, with significant contributions from Bioscience Managers and Trudell Medical International. The funds will support the expansion of Adherium’s Hailie® Smartinhaler® platform in the United States, aiming to onboard 1,800 active patients in the next six months and 9,000 by the end of 2025. This financial backing is seen as a positive indicator of the company’s growth prospects and its strategic focus on the US market, where it plans to capitalize on new reimbursement codes and advanced AI capabilities.
Adherium Ltd. has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of March 13, 2025. This change in substantial holding, which involved the purchase and sale of 14,000,000 ordinary shares by J.P. Morgan Securities Australia Limited, may impact Adherium’s shareholder structure and influence its market perception.